Radioimmunotherapy of pancreatic cancer xenografts in nude mice using 90Y-labeled anti-α6β4 integrin antibody

Oncotarget

Volumn 7, Issue 25, 2016, Pages 38835-38844

  Aung, Winn ^a   Tsuji, Atsushi B ^a   Sudo, Hitomi ^a   Sugyo, Aya ^a   Ukai, Yoshinori ^b   Kouda, Katsushi ^b   Kurosawa, Yoshikazu ^c   Furukawa, Takako ^a   Saga, Tsuneo ^a  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b Perseus Proteomics   (Japan)

^c FUJITA HEALTH UNIVERSITY   (Japan)

Author keywords

Pancreatic tumor; Radiolabeled antibody; Targeted radioimmunotherapy; Yttrium 90; 6 4 integrin

Indexed keywords

DNA; HISTONE H2AX; KI 67 ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY ALPHA6BETA4 INTEGRIN; UNCLASSIFIED DRUG; YTTRIUM 90; ALPHA6BETA4 INTEGRIN; FLUORODEOXYGLUCOSE F 18; YTTRIUM; YTTRIUM-90;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD ANALYSIS; BODY WEIGHT; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER INHIBITION; CONTROLLED STUDY; DNA DAMAGE; DOUBLE ADMINISTRATION; DRUG DOSE; DRUG DOSE COMPARISON; DRUG EFFICACY; FEMALE; HEMATOLOGICAL PARAMETERS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; KIDNEY FUNCTION; LIVER FUNCTION; MOUSE; NONHUMAN; NUDE MOUSE; PANCREAS CANCER; RADIATION DOSE FRACTIONATION; RADIOIMMUNOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TREATMENT RESPONSE; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CHEMISTRY; DRUG SCREENING; IMMUNOLOGY; PANCREAS TUMOR; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; TISSUE DISTRIBUTION; TUMOR CELL CULTURE; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; BODY WEIGHT; CELL LINE, TUMOR; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; INTEGRIN ALPHA6BETA4; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOIMMUNOTHERAPY; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS; YTTRIUM RADIOISOTOPES;

EID: 84978145322     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.9631     Document Type: Article

References (38)

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136:E359-386.
2. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell. 1992; 69:11-25.
3. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010; 10:9-22.
4. Sonnenberg A, Calafat J, Janssen H, Daams H, Vanderraaijhelmer LMH, Falcioni R, Kennel SJ, Aplin JD, Baker J, Loizidou M, Garrod D. Integrin-Alpha-6-Beta-4 complex is located in hemidesmosomes, suggesting a major role in epidermal-cell basement-membrane Adhesion. J of Cell Biol. 1991; 113:907-917.
5. Falcioni R, Sacchi A, Resau J, Kennel SJ. Monoclonal antibody to human carcinoma-associated protein complex: quantitation in normal and tumor tissue. Cancer Res. 1988; 48:816-821.
6. Rabinovitz I, Mercurio AM. The integrin alpha 6 beta 4 and the biology of carcinoma. Biochem Cell Biol. 1996; 74:811-821.
7. Mercurio AM, Rabinovitz I. Towards a mechanistic understanding of tumor invasion-lessons from the alpha6beta 4 integrin. Semin Cancer Biol. 2001; 11:129-141.
8. Bon G, Folgiero V, Di Carlo S, Sacchi A, Falcioni R. Involvement of alpha(6)beta(4) integrin in the mechanisms that regulate breast cancer progression. Breast Cancer Research. 2007; 9.
9. Soung YH, Gil HJ, Clifford JL, Chung J. Role of alpha6beta4 integrin in cell motility, invasion and metastasis of mammary tumors. Curr Protein Pept Sci. 2011; 12:23-29.
10. Beaulieu JF. Integrin alpha6beta4 in colorectal cancer. World J Gastrointest Pathophysiol. 2010; 1:3-11.
11. Noh TW, Soung YH, Kim HI, Gil HJ, Kim JM, Lee EJ, Chung J. Effect of (beta)4 integrin knockdown by RNA interference in anaplastic thyroid carcinoma. Anticancer Res. 2010; 30:4485-4492.
12. Lipscomb EA, Mercurio AM. Mobilization and activation of a signaling competent alpha6beta4integrin underlies its contribution to carcinoma progression. Cancer Metastasis Rev. 2005; 24:413-423.
13. Cruz-Monserrate Z, Qiu S, Evers BM, O'Connor KL. Upregulation and redistribution of integrin alpha6beta4 expression occurs at an early stage in pancreatic adenocarcinoma progression. Mod Pathol. 2007; 20:656-667.
14. Gleason B, Adley B, Rao MS, Diaz LK. Immunohistochemical detection of the beta4 integrin subunit in pancreatic adenocarcinoma. J Histochem Cytochem. 2005; 53:799-801.
15. Logsdon CD, Simeone DM, Binkley C, Arumugam T, Greenson JK, Giordano TJ, Misek DE, Kuick R, Hanash S. Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res. 2003; 63:2649-2657.
16. Kurosawa G, Akahori Y, Morita M, Sumitomo M, Sato N, Muramatsu C, Eguchi K, Matsuda K, Takasaki A, Tanaka M, Iba Y, Hamada-Tsutsumi S, Ukai Y, et al. Comprehensive screening for antigens overexpressed on carcinomas via isolation of human mAbs that may be therapeutic. Proc Natl Acad Sci U S A. 2008; 105:7287-7292.
17. Aung W, Tsuji AB, Sudo H, Sugyo A, Furukawa T, Ukai Y, Kurosawa Y, Saga T. Immunotargeting of Integrin alpha6beta4 for Single-Photon Emission Computed Tomography and Near-Infrared Fluorescence Imaging in a Pancreatic Cancer Model. Mol Imaging. 2016; doi: 10.1177/1536012115624917.
18. Kassis AI. Therapeutic radionuclides: biophysical and radiobiologic principles. Semin Nucl Med. 2008; 38:358-366.
19. Sharkey RM, Behr TM, Mattes MJ, Stein R, Griffiths GL, Shih LB, Hansen HJ, Blumenthal RD, Dunn RM, Juweid ME, Goldenberg DM. Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22. Cancer Immunol Immunother. 1997; 44:179-188.
20. DeNardo GL, Schlom J, Buchsbaum DJ, Meredith RF, O'Donoghue JA, Sgouros G, Humm JL, DeNardo SJ. Rationales, evidence, and design considerations for fractionated radioimmunotherapy. Cancer. 2002; 94:1332-1348.
21. Stewart RL, O'Connor KL. Clinical significance of the integrin alpha6beta4 in human malignancies. Lab Invest. 2015; 95:976-986.
22. de Jong M, Breeman WA, Valkema R, Bernard BF, Krenning EP. Combination radionuclide therapy using 177Lu-and 90Y-labeled somatostatin analogs. J Nucl Med. 2005; 46:13S-17S.
23. Brouwers AH, van Eerd JE, Frielink C, Oosterwijk E, Oyen WJ, Corstens FH, Boerman OC. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re. J Nucl Med. 2004; 45:327-337.
24. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000; 182:311-322.
25. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem. 1998; 273:5858-5868.
26. Sugyo A, Tsuji AB, Sudo H, Okada M, Koizumi M, Satoh H, Kurosawa G, Kurosawa Y, Saga T. Evaluation of efficacy of radioimmunotherapy with 90Y-labeled fully human anti-transferrin receptor monoclonal antibody in pancreatic cancer mouse models. PLoS One. 2015; 10:e0123761.
27. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer. 2006; 6:583-592.
28. Onthank DC, Liu S, Silva PJ, Barrett JA, Harris TD, Robinson SP, Edwards DS. 90Y and 111In complexes of a DOTA-conjugated integrin alpha v beta 3 receptor antagonist: different but biologically equivalent. Bioconjug Chem. 2004; 15:235-241.
29. Contractor KB, Aboagye EO. Monitoring predominantly cytostatic treatment response with 18F-FDG PET. J Nucl Med. 2009; 50:97S-105S.
30. Avril NE, Weber WA. Monitoring response to treatment in patients utilizing PET. Radiol Clin North Am. 2005; 43:189-204.
31. Veeravagu A, Liu Z, Niu G, Chen K, Jia B, Cai W, Jin C, Hsu AR, Connolly AJ, Tse V, Wang F, Chen X. Integrin alphavbeta3-targeted radioimmunotherapy of glioblastoma multiforme. Clin Cancer Res. 2008; 14:7330-7339.
32. Niu G, Sun X, Cao Q, Courter D, Koong A, Le QT, Gambhir SS, Chen X. Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma. Clin Cancer Res. 2010; 16:2095-2105.
33. Jeraj R, Bradshaw TJ, Simoncic U. Molecular Imaging to Plan Radiotherapy and Evaluate its Efficacy. J Nucl Med. 2015; 56:1752-1765.
34. Czernin J, Phelps ME. Positron emission tomography scanning: current and future applications. Annu Rev Med. 2002; 53:89-112.
35. Sogawa C, Tsuji AB, Sudo H, Sugyo A, Yoshida C, Odaka K, Uehara T, Arano Y, Koizumi M, Saga T. C-kit-targeted imaging of gastrointestinal stromal tumor using radiolabeled anti-c-kit monoclonal antibody in a mouse tumor model. Nucl Med Biol. 2010; 37:179-187.
36. Wong FC. MIRD: Radionuclide Data and Decay Schemes. J Nucl Med. 2009; 50: 2091-2091. doi: 10.2967/jnumed. 109.069948.
37. Yoshida C, Tsuji AB, Sudo H, Sugyo A, Kikuchi T, Koizumi M, Arano Y, Saga T. Therapeutic efficacy of c-kit-targeted radioimmunotherapy using 90Y-labeled antic-kit antibodies in a mouse model of small cell lung cancer. PLoS One. 2013; 8:e59248.
38. Sudo H, Tsuji AB, Sugyo A, Ogawa Y, Sagara M, Saga T. ZDHHC8 knockdown enhances radiosensitivity and suppresses tumor growth in a mesothelioma mouse model. Cancer Sci. 2012; 103:203-209.